Kaiku Health, Oulu University Hospital and Docrates Cancer Center have published first data on the symptoms reported by cancer patients receiving immune checkpoint inhibitor (ICI) therapies in a real-world setting.
The purpose of the study was to investigate whether symptoms reported by cancer patients using the Kaiku Health ICI module corresponded to symptoms reported in earlier clinical trials. The study also sought to investigate the feasibility of electronic self-reporting of symptoms and whether there are significant correlations between different reported symptoms.
To the authors’ best knowledge, the current study is the first of its kind investigating electronic Patient-Reported Outcomes (ePROs) in the follow-up of cancer patients receiving ICI therapies.
Patients treated with immune checkpoint inhibitors PD-1, PD-L1 and CTLA-4 antibodies at the study centres were provided with the Kaiku Health web application to report their symptoms and quality of life in real-time. Built-in algorithms in the Kaiku Health platform screened the patients’ symptom data and gave an assessment on the severity of symptoms that may have been potential signs of immune-related adverse events. The algorithms alerted the care team according to the severity of symptoms.
“The results are first to come out of such study involving self-reporting of patients undergoing immune checkpoint inhibitor therapy. We still have limited knowledge of the adverse effects when treating patients with ICI treatments. The treatment-related adverse events may include the body’s own immune system attacking healthy tissues, which is why it is very important to get a better understanding of the immunotoxicities of treatments. The Kaiku Health algorithms were able to detect symptoms of differing severities, allowing us to intervene at an earlier stage. The correlations found between certain adverse events and possible clinical benefits was extremely interesting, and sets a precedent for future research”, concludes Docent Jussi Koivunen, MD at Oulu University Hospital.
The study concludes that the observed real-world patient-reported symptom data strongly corresponds to the data reported in previous clinical trials. The analysis shows that there is significant negative correlation between patient-reported symptoms and predicted immunotoxicities, such as rash and itching, and disease progression-related symptoms, such as cough and shortness of breath. This supports the hypothesis that incidence of immune-related adverse events may indicate a potential clinical benefit for the patient.
“This study shows that utilizing digital symptom tracking is feasible in better engaging patients in symptom self-reporting during ICI treatments. This helps in gaining a more comprehensive understanding on the onset and presence of immune-related adverse events. We are excited to continue our work together with researchers in order to gain more understanding on the correlation between patient-reported adverse events and clinical variables”, says Henri Virtanen, Chief Product Officer at Kaiku Health.
The article “ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study” was published in Journal of Cancer Research and Clinical Oncology. It is accessible in here: https://doi.org/10.1007/s00432-018-02835-6
For further information, please contact
Henri Virtanen, Chief Product Officer
+358 45 276 3593